High Tide Welcomes Historic Executive Order on Cannabis Rescheduling and Medicare Reimbursements for CBD Products

Core Insights - The Company is assessing U.S. licensing pathways for its Canna Cabana retail brand and is evaluating Medicare-aligned product categories for its CBD brands, NuLeaf Naturals and FAB CBD [1][3] Group 1: Regulatory Developments - The Executive Order from the White House is a significant step in U.S. federal cannabis reform, indicating bipartisan support for cannabis and CBD policy changes [2] - The Centers for Medicare & Medicaid Services is expected to launch a pilot program allowing certain Medicare beneficiaries to receive CBD treatments at no cost, which could enhance market opportunities for the Company [1][2] Group 2: Business Strategy - The Company is exploring the feasibility of expanding Canna Cabana into the U.S. through a licensing model while ensuring compliance with NASDAQ and TSXV listings [3] - NuLeaf Naturals and FAB CBD are developing Medicare-aligned product categories to potentially be included in Medicare Advantage supplemental benefits, leveraging their CGMP-certified operations and large customer base [3] Group 3: Market Position - High Tide operates the largest cannabis retail chain in Canada, with 218 domestic and 1 international location, holding a 12% market share [6] - The Company has been recognized as one of Canada's Top Growing Companies and ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023 [8]